COLL vs RTX · P/E 17, rev $181.9M vs P/E 36, rev $88.60B
Collegium Pharmaceutical Inc (COLL) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the COLL and RTX stock pages for the full models.
Not investment advice.